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Summary
The Nf1 tumor suppressor encodes a GTPase-activating protein for Ras. Previous work has implicated hyperactive Ras
in the aberrant growth of Nf1-deficient cells; however, there are limited data on which effectors modulate specific pheno-
types. To address this, we generated myeloid cell lines by infecting fetal liver cells with a retrovirus encoding a truncated
allele of c-Myb. Granulocyte-macrophage colony stimulating factor (GM-CSF) promoted the survival of wild-type Myb cells
in a dose-dependent manner. By contrast, Nf1-deficient myeloid cells deprived of growth factors, were resistant to apoptosis
due to hyperactivation of the phosphoinositide-3-OH kinase/protein kinase B cascade. Nf1/ cells also demonstrated
growth factor-independent proliferation and upregulation of GM-CSF mRNA production that were dependent upon Raf/
MEK/ERK signaling. These data link specific Ras effectors with discrete cellular phenotypes in Nf1-deficient cells.
Introduction JMML is a relentless myeloproliferative disorder (MPD) char-
acterized by overproduction of myeloid cells that infiltrate multi-
Neurofibromatosis type 1 (NF1) is the most common inherited ple tissues (reviewed in Arico et al., 1997; Emanuel et al., 1996).
cancer predisposition syndrome with an incidence of 1 in 3500 JMML cells show hypersensitive growth of large colony forming
(Riccardi and Eichner, 1986). Affected persons are at increased unit granulocyte-macrophage (CFU-GM) progenitor colonies in
risk of developing specific benign and malignant neoplasms methylcellulose cultures stimulated with granulocyte-macro-
that primarily arise in cells derived from the embryonic neural phage colony stimulating factor (GM-CSF) (Emanuel et al.,
crest (Side and Shannon, 1998). In addition, children (but not 1991b; Schiro et al., 1994). Homozygous Nf1 mutant embryos
adults) with NF1 are predisposed to myeloid malignancies, par- fail around E13 with cardiovascular defects (Brannan et al.,
ticularly juvenile myelomonocytic leukemia (JMML) (Bader and 1994; Jacks et al., 1994); however, approximately 10% of het-
Miller, 1978; Shannon et al., 1992; Stiller et al., 1994). The NF1 erozygous (Nf1/) mutant mice spontaneously develop an MPD
gene encodes neurofibromin, a GTPase-activating protein that models JMML (Jacks et al., 1994). Nf1/ fetal liver cells
(GAP) that negatively regulates p21ras (Ras) output by accelerat- show hypersensitive CFU-GM progenitor growth in response
ing GTP hydrolysis on Ras (reviewed in Bernards, 1995; Boguski to GM-CSF that is similar to human JMML cells (Bollag et al.,
and McCormick, 1993; Donovan et al., 2002). Genetic and bio- 1996; Largaespada et al., 1996), and adoptive transfer of these
chemical analysis of primary tumors and of tumor-derived cell mutant cells consistently induces a JMML-like MPD in irradiated
recipient mice (Largaespada et al., 1996; Zhang et al., 1998).lines demonstrated that NF1 and its murine homolog (Nf1) func-
tion as tumor suppressor genes, and revealed aberrant activa- Further studies in which fetal liver cells doubly mutant at the
Gmcsf and Nf1 loci were generated and transferred intotion of Ras effector pathways in Nf1-deficient cells (reviewed
in Cichowski and Jacks, 2001; Side and Shannon, 1998). Gmcsf/ or wild-type recipients have underscored the central
S I G N I F I C A N C E
Hyperactive Ras is among the most common biochemical abnormalities found in cancer cells and results from oncogenic RAS point
mutations and other genetic lesions. Based on this, the Ras-activated signaling pathways are being pursued intensively as potential
targets for drug discovery. However, because Ras interacts with multiple downstream effectors, the contribution of individual Ras-
dependent signaling pathways to tumorigenesis is largely unknown. We show that hyperactivation of the PI3 kinase/PKB and Raf/
MEK/ERK cascades coordinately deregulates the growth of myeloid cells through discrete effects on survival, proliferation, and
autocrine expression of growth factors. These findings, which underscore the pleiotropic effects of hyperactive Ras on growth control,
have implications for the development of therapeutics that may target specific effectors.
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role of aberrant GM-CSF signaling in initiating and maintaining Nf1/ Myb lines proliferated robustly while wild-type cells dem-
onstrated variable rates of growth. We first compared apoptosisthis MPD in vivo (Birnbaum et al., 2000).
In 1989, Gonda and coworkers (Gonda et al., 1989a) devel- in wild-type and Nf1/ Myb lines over a range of GM-CSF
concentrations. Growing wild-type and Nf1/ Myb cells wereoped cell lines that resemble early granulocyte-macrophage
progenitors by infecting murine fetal liver cells with a retrovirus washed, incubated overnight with 0–10 ng/ml of GM-CSF, and
stained with Annexin V to detect apoptosis. There was a strongencoding a truncated allele of c-Myb. Cells transformed with this
REDMyb(CT3) virus are dependent on serum and hematopoietic dose-dependent effect of GM-CSF on the survival of wild-type
Myb cells with 80% of the cells undergoing apoptosis in thegrowth factors and are especially responsive to GM-CSF
(Gonda et al., 1993). Here we show that Nf1/ Myb cells are absence of GM-CSF and 95% surviving at 10 ng/ml (Figure
2A). By contrast, Nf1/ Myb cells were resistant to apoptosishypersensitive to GM-CSF in tissue culture, resist apoptosis
upon growth factor withdrawal, and proliferate in the absence of induced by GM-CSF withdrawal (Figure 2B). Using DNA lad-
dering as an alternative method for measuring apoptosis gaveexogenous cytokines. These cells also demonstrate constitutive
activation of Ras effector pathways, and we find that the phos- similar results (data not shown). Nf1/ Myb cells were cultured
with inhibitors of MEK (PD184352) or PI3K (LY294002) to ad-phoinositide-3-OH kinase/protein kinase B (PI3K/PKB) is essen-
tial for survival in the absence of cytokines. Nf1/ Myb cells also dress if signaling though the Raf/MEK/ERK and PI3K/PKB cas-
cades is required for the survival in the absence of exogenousproliferate without exogenous growth factors and demonstrate
elevated levels of GM-CSF mRNA that are dependent upon GM-CSF. To reduce the potential for nonspecific interactions
with other signaling molecules, we sought to expose the cells toactivation of the Raf/MEK/ERK cascade. Thus, the pleiotropic
effects of hyperactive Ras in Nf1-deficient cells are mediated the lowest effective doses of PD184352 and LY294002. Limited
data have been published on the minimal concentration ofthrough discrete downstream signaling cascades, which coop-
erate to undermine growth control. Aberrant GM-CSF expres- PD184352 that is required to block activation of ERK kinase.
We therefore performed a titration and showed that 10 Msion is likely to reinforce aberrant growth through an autocrine
loop that further deregulates Ras signaling. restored elevated levels of phosphorylated ERK detected in
Nf1/ Myb cells (see following section and Figure 4B) to normal,
while 1 M did not consistently have this effect. In later experi-Results
ments, we found that 2 M of PD184352 was the minimal effec-
tive dose of PD184352. By contrast, LY294002 has been usedCharacterization of Myb-transformed cells
A retrovirus was constructed in the murine stem cell virus extensively and we selected a dose of 20 M. LY294002 effi-
ciently induced apoptosis of Nf1/ Myb cells (Figure 2C) while(MSCV) backbone to coexpress the truncated Myb-CT peptide
with a green fluorescent protein (GFP) marker (see Experimental PD184352 was much less effective (Figure 2D). Together, these
results suggest that loss of Nf1 deregulates hematopoieticProcedures). Infections were performed by transiently transfect-
ing Phoenix packaging cells with this MSCV-Myb-GFP virus, growth, at least in part, by rendering myeloid precursors less
dependent upon cytokines for survival, and they show that thatfollowed by co-culture with E12.5–E13.5 fetal liver cells to gener-
ate stable Myb lines as described previously (Gonda et al., the PI3K/PKB pathway is integral to this phenotype. Because
Nf1/ Myb cells maintained in 20% fetal calf serum continued1989b). After 1–2 weeks in culture, Nf1/ and wild-type Myb
cells uniformly expressed the myelomonocytic marker Mac1 to grow (albeit at a reduced rate) in the absence of GM-CSF,
bromo-dioxyuridine (Brd-U) incorporation was measured to as-and the neutrophilic antigen Gr1 and showed variable expres-
sion of Sca1, which marks hematopoietic cells with high repopu- sess progression through the cell division cycle. Remarkably,
15%–20% of Nf1/ Myb cells incorporated Brd-U; this waslating potential (data not shown). Stable Myb lines that emerged
after 2–3 months were Mac1, Gr1, and Sca1 (Figure 1A), reduced dramatically by exposure to PD184352 (Figure 3).
and 5%–10% of these cells formed CFU-GM colonies in the
presence of saturating concentrations of GM-CSF. There were Ras activation and signaling in Myb cells
In pilot experiments, 80% of wild-type Myb cells deprived ofmarked quantitative and qualitative differences between CFU-
GM colonies grown from wild-type and Nf1/ Myb cells. GM-CSF for 4 hr were viable as assessed by absence of Annexin
V labeling (data not shown). Signaling experiments were there-Whereas wild-type Myb cells did not form CFU-GM in the ab-
sence of exogenous GM-CSF, Nf1/ cells consistently showed fore performed 4 hr after GM-CSF removal on cells that were
maintained in 20% fetal calf serum to avoid the confoundingcytokine-independent colony growth (Figure 1B). Wild-type cells
cultured with 0.1 ng/ml of GM-CSF generated CFU-GM that effects of cell death on biochemical endpoints. Under these
conditions, Nf1/ Myb cells demonstrated a marked increasewere compact and contained relatively few cells, while 1 ng/ml
induced the formation of larger colonies with a spreading mor- in the percentage of Ras in the active, GTP bound conformation
(Figure 4A). These elevated levels of Ras-GTP were associatedphology. By contrast, CFU-GM grown from Nf1/ Myb cells
were more diffuse, and enormous CFU-GM containing thou- with basal activation of ERK and PKB, and with hyperactivation
following exposure to GM-CSF (Figures 4B and 4C). ERK kinasesands of cells were observed at saturating concentrations of
GM-CSF (Figure 1C). Thus, Nf1/ Myb cells mimic the GM- activity was also induced to a lesser degree by interleukin 3
(IL-3) (Figure 4B). Nf1/ and wild-type Myb cells containedCSF hypersensitivity and morphologic abnormalities that are in
vitro hallmarks of CFU-GM colonies grown from JMML patients. similar levels of ERK (Figure 4B); however, the total amount of
PKB was higher in the Nf1/ cells (data not shown).
Apoptosis and proliferation of Myb cells
Wild-type and Nf1/ Myb lines were established and maintained Production of GM-CSF by Nf1/ Myb cells
The data presented above raised the possibility that an externalin culture medium supplemented with 20% fetal calf serum and 1
ng/ml of recombinant murine GM-CSF. Under these conditions, stimulus such as autocrine production of GM-CSF might promote
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Figure 1. Characteristics of Myb-infected cell lines
A: Immunophenotypes of Myb cells. Wild-type cells are shown on the left and Nf1/ cells are on the right.
B: CFU-GM colony growth from Myb cells (SEM). Data were pooled from three experiments.
C: Morphology of CFU-GM colonies grown from Myb cells.
the survival and proliferation of Nf1/ Myb cells. To address quences of Nf1 inactivation because they manifest growth and
this question, we performed quantitative real time polymerase differentiation characteristics of primary myeloid progenitors
chain reaction (Taqman) analysis and found that GM-CSF mRNA and are particularly dependent upon GM-CSF for proliferation
levels were 17–113 times higher in Nf1/ Myb cells versus wild- and survival (Gonda et al., 1993, 1989b). Furthermore, leukemias
type cells (Figure 5A). To ascertain the role of signaling through that develop in heterozygous Nf1 mutant mice infected with the
the Raf/MEK/ERK and PI3K/PKB pathways on GM-CSF expres- BXH-2 retrovirus frequently demonstrate both inactivation of
sion, mRNA levels were measured in Nf1/ Myb cells that were the wild-type Nf1 allele and integrations at the Epi1 locus, which
treated with PD184352 (2 M) or LY294002 (20 M). PD184352 is 30–40 kb downstream of Myb (Blaydes et al., 2001). These
induced a dramatic reduction in the amount of GM-CSF mRNA, data suggest that loss of Nf1 and deregulated expression of Myb
while LY294002 had inconsistent effects (Figure 5B). We also cooperate in myeloid leukemogenesis in vivo. We previously
used a neutralizing rat antibody to murine GM-CSF to ascertain detected elevated levels of Ras-GTP in JMML cells from children
the functional significance of elevated levels of GM-CSF mRNA with NF1 (Bollag et al., 1996), and Largaespada et al. (1996)
in Nf1/ Myb cells. In these experiments, the cells were cultured reported sustained hyperactivation of Ras-GTP in Nf1/ Myb
in the absence of exogenous GM-CSF and antibody was added
cells that were stimulated with GM-CSF. Our studies showingat the beginning of the experiment only (one dose) or at the
constitutive activation of the Raf/MEK/ERK effector pathwaystart and 12 hr later (two doses). A single dose of the antibody
with hyperactivation in response to GM-CSF extend this workhad no effect; however, significant apoptosis was detected
and are consistent with data from primary Nf1/ c-kit-positiveafter 48 hr in cells that received two doses of the antibody (Fig-
bone marrow cells (Zhang et al., 1998) and heterozygous Nf1-ure 5C).
deficient bone marrow-derived mast cells (Ingram et al., 2000).
We extensively characterized the cellular consequences ofDiscussion
deregulated Ras signaling in Nf1/ Myb cells. GM-CSF pre-
vented apoptosis in wild-type Myb cells in a dose-dependentMyb-transformed fetal liver cells provide a relevant experimental
system for interrogating the cellular and biochemical conse- manner, and loss of Nf1 allowed Myb-transformed cells to sur-
CANCER CELL : DECEMBER 2002 509
R E P O R T
Figure 2. Apoptosis of Myb cells measured by annexin V staining
Increased fluorescence intensity on the horizontal axis corresponds to annexin V labeling.
A: Wild-type Myb cells. Note that the proportion of Annexin V-positive cells decreases with increasing GM-CSF concentrations.
B: Nf1/ cells survive without GM-CSF.
C: LY294002 induces apoptosis of Nf1/ Myb cells cultured in the absence of GM-CSF. The left plot shows wild-type cells cultured without GM-CSF (positive
control), the middle plot is Nf1/ cells, and the right plot is Nf1/ cells cultured with the inhibitor.
D: PD184352 has limited effects on the survival of Nf1/ Myb cells. As in C, the cells were cultured in the absence of GM-CSF. The left plot is wild-type cells
(positive control), and the three right plots are Nf1/ cells cultured in the absence or presence of PD184352.
vive without added cytokines. Experiments using small molecule a negative regulator of PI3K signaling, develop a MPD that
resembles the disorder seen in recipients of Nf1/ fetal liverinhibitors demonstrated a primary role of the PI3K/PKB pathway
in conferring resistance to apoptosis in Nf1/ Myb cells. Inter- cells (Huber et al., 1998; Liu et al., 1999). Like Nf1/ Myb cells,
neutrophils and mast cells from SHIP mutant mice show defec-estingly, mice deficient in the inositol 5 phosphatase SHIP,
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Figure 3. Proliferation of Nf1/ Myb cells in the
absence of GM-CSF
Peaks corresponding to Brd-U-positive cells are
shifted to the right on the horizontal axis. In this
experiment, 18.1% of untreated cells incorpo-
rated Brd-U versus 6.8% of cells exposed to 2 M
PD184352, and 2.3% in the presence of 10 M of
inhibitor.
tive apoptotic responses to growth factor withdrawal (Liu et al., in mice heterozygous for mutations in Nf1 and p53. Growth of
these lines was potently inhibited by LY294002. These studies1999). We also found that Nf1/ Myb cells proliferated in the
absence of GM-CSF; this phenotype was susceptible to inhibi- in other lineages that are affected in persons with NF1 disease
suggest that growth factor hypersensitivity and defective apo-tion of the Raf/MEK/ERK cascade. These biochemical data im-
plicate deregulation of PI3K/PKB and Raf/MEK/ERK signaling ptosis mediated through deregulated PI3K/PKB are common
molecular defects that contribute to aberrant growth and tumori-as mediating distinct and cooperative effects in Nf1-deficient
cells. genesis in distinct Nf1-deficient cell types.
Autocrine production of GM-CSF by Nf1/ Myb cells isCultured Nf1-deficient embryonic neurons display neuro-
trophin-independent survival and growth factor hypersensitivity intriguing in light of the central and specific role of GM-CSF in
the pathogenesis of JMML and in the corresponding murine(Vogel et al., 1995). Other studies using dominant-negative ad-
enoviruses implicated the PI3K/PKB pathway, but not Raf/MEK/ MPD. The GM-CSF promoter contains adjacent Ets and AP-1
elements that are activated by signaling through the Raf/MEK/ERK signaling, as essential for the survival of wild-type and
Nf1/ neurons (Klesse and Parada, 1998). Most recently, Li et ERK cascade (Wang et al., 1994); this is consistent with our
data showing that PD184352 treatment markedly reduced GM-al. (2002) detected amplification of the epidermal growth factor
receptor and activation of the Raf/MEK/ERK and PI3K/PKB cas- CSF mRNA levels in Nf1/ Myb cells. Studies in JunB mutant
cells have provided additional insights implicating deregulatedcades in cell lines derived from soft tissue tumors that developed
Figure 4. Activation of Ras, ERK, and PKB in wild-
type and Nf1/ Myb cells
The cells were assayed 4 hr after GM-CSF was
removed.
A: Total Ras and Ras GTP levels. An aliquot corre-
sponding to 1/25th of the total lysate was used to
compare total Ras levels in wild-type and mutant
cells. The control K-Ras peptide migrates more
slowly because it contains an epitope tag.
B: Phosphorylated ERK and total ERK levels in Myb
cells stimulated with GM-CSF or interleukin-3 (IL-3)
for 10 min. The control lane is from NIH 3T3 cells
stimulated with platelet-derived growth factor.
C: Basal and GM-CSF-stimulated PKB kinase ac-
tivities were determined by measuring phosphor-
ylation of a GSK substrate.
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Figure 5. Expression of GM-CSF mRNA in Myb
cells
A: GM-CSF mRNA levels in wild-type and Nf1/
Myb cells.
B: Effects of PD184352 (2 M) and LY29004 (20
M) on GM-CSF mRNA levels in Myb cells. RNA
was extracted at different times from six individ-
ual subcultures of a stable Nf1/ Myb line to ob-
tain the data shown in A and from four subcul-
tures for B.
C: Apoptosis of Nf1/ Myb cells exposed to a
neutralizing rat-anti-mouse GM-CSF antibody.
Nf1/ Myb cells cultured in the absence of GM-
CSF for 48 hr received either no antibody, a single
dose of the antibody at the start of the experi-
ment (final concentration 4 g/ml), or this dose
at the start of the experiment and a second dose
12 hr later. Annexin V staining was performed
after 48 hr. The percentage of Annexin V-positive
cells was low in cells that were not treated with
antibody or received a single dose (14.5% and
17.5% in this experiment). By contrast, 38% of the
Nf1/ Myb cells that received both doses of anti-
body were stained by Annexin V.
GM-CSF signaling in the development of MPD. JunB is a com- although JMML bone marrow cells show intrinsic GM-CSF hy-
persensitivity in colony forming assays (Emanuel et al., 1991b;ponent of the AP-1 complex that functionally antagonizes the
effects of c-Jun. JunB has prominent repressor activity, but Zhang et al., 1998), GM-CSF production is also increased in
50% of JMML samples (Emanuel et al., 1991a; Freedman etmay also activate transcription in certain contexts (Chiu et al.,
1989; Hsu et al., 1993). Homozygous JunB mutant embryos fail al., 1992; Gualtieri et al., 1989). These observations suggest
that growth factor concentrations are limiting in the bone mar-between E8.5 and E10 with vascular defects (Schorpp-Kistner
et al., 1999); however, high levels of GM-CSF production by row stroma and that the leukemic clone gains an additional
proliferative advantage through autocrine production of GM-immortalized JunB/ fibroblasts induce human keratinocytes
to form aberrant epithelial layers in orthotopic cultures (Szabow- CSF. Nf1/ Myb cell lines appear to model this aspect of the
human disease. It is likely that loss of Nf1 has effects on apopto-ski et al., 2000). Expressing a JunB transgene from the ubiquitin
C promoter rescued JunB/ embryos and resulted in normal sis that are independent of GM-CSF (the data in Figure 1 argue
for this), and that overproduction of GM-CSF is an acquireddevelopment (Passegue et al., 2001). Surprisingly, the ubiqutin
C transgene was silenced in myeloid cells by an epigenetic event that cooperates in leukemogenesis. This idea is consistent
with the fact that human JMML cells are universally hypersensi-mechanism, and these JunB/ Ubi-junB mice consistently de-
veloped MPD, which was associated with selective hypersensi- tive to GM-CSF in culture, yet only about half of these leukemias
produce excessive levels of GM-CSF.tivity to GM-CSF and with overexpression of the  chain of the
GM-CSF receptor (Passegue et al., 2001). Similarities between It will be of interest to explore the contribution of autocrine
mechanisms to aberrant growth in disorders such as CML,the MPDs associated with inactivation of Nf1 and JunB implicate
misregulation of AP-1 target genes downstream of Ras-GTP as CMML, multiple myeloma, and polycythemia vera in which
malignant hematopoietic cells undergo some differentiation. Fi-a common pathogenic mechanism.
Chronic myeloid leukemia (CML), chronic myelomonocytic nally, small molecules that either inhibit hyperactive Ras or inter-
fere with paracrine/autocrine loops represent rational therapeu-leukemia (CMML), and JMML are clonal disorders in which the
malignant stem cells retain the capacity to differentiate. In tic strategies for improving the dismal prognosis in JMML, and
may prove efficacious in other NF1-associated cancers. How-JMML, there is over-production of monocytes that infiltrate into
the liver, spleen, and other tissues. Removing these monocytes ever, our data implicating coordinate hyperactivation of the
PI3K/PKB and Raf/MEK/ERK cascades in the aberrant survivalby adherence depletion abrogates the hypersensitive pattern
of CFU-GM colony growth that is a cellular hallmark of JMML and proliferation of Nf1/ myeloid cells also suggest that tar-
geting a single effector cascade may not fully suppress the(Bagby et al., 1988; Emanuel et al., 1991a; Estrov et al., 1986);
this suggested a paracrine mechanism of action. Importantly, growth advantage found in cells with hyperactive Ras.
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Experimental procedures H21 at 37C in 5% CO2 for 4 hr. Aliquots of cells (1 	 106 per condition)
were stimulated with growth factors for 10 min before lysis in Holstrom
buffer (Holmstrom et al., 1998). Phospho-ERK levels were measured byMSCV-Myb construction and fetal liver cell transduction
The mice used in these studies were housed in the UCSF Animal Care Western blotting using a phospho-p44/42 MAPK antibody (Catalog #9101,
Cell Signaling). The blots were stripped and probed with anti-ERK antibodyFacility, and the study procedures were approved by the Committee on
Animal Research. Nf1 mutant mice were provided by Dr. Tyler Jacks (Jacks (Catalog #sc-154-G, Santa Cruz Biotechnologies, Santa Cruz, California) to
control for protein loading. PKB/Akt kinase activity was detected using theet al., 1994). Nf1/ mice on a mixed C57Bl/6 	 129/Sv background were
mated to generate fetal liver cells. Single cell suspensions of E13.5 fetal liver Akt Kinase Assay Kit (Cell Signaling), which utilizes GSK fusion protein as
a PKB substrate. Phospho-GSK levels were detected by Western blottingcells were prepared and embryo genotypes were determined as described
(Birnbaum et al., 2000; Zhang et al., 1998). Fetal liver cells were cultured in according to the manufacturer’s instructions.
50 ng/ml stem cell factor (SCF) and 50 ng/ml of IL-6 (Peprotech, Rocky
Hill, New Jersey) for 2 days in 20% FBS DMEM-H21 containing 20 mM GM-CSF production by cultured Myb cells and antibody treatment
Cells suspended at 1 	 106 per ml in 2 ml wells were washed to removeL-glutamine, 10 g/ml streptomycin, and 10 units/ml penicillin G (UCSF
Cell Culture Facility). Phoenix packaging cells were cultured until they were GM-CSF and cultured as described above. After 4 hr, the cells were centri-
fuged and lysed in 1 ml of Trizol (Invitrogen). RNA prepared according to60%–80% confluent, then transfected with the MSCV-MybCT plasmid using
either calcium phosphate or Lipofectamine PLUS reagents (Invitrogen, Carls- the manufacturer’s instructions was reverse transcribed into cDNA using
Taqman Reverse Transcription Reagents (Applied Biosystems, Foster City,bad, California). In our initial experiments, 1 	 106 fetal liver cells were
infected with 1.5 ml of viral supernatant in the presence of 5 g/ml polybrene California). Real time polymerase chain reaction analysis was performed on
an ABI PRISM 7700 Sequence Detection System using murine GM-CSFand centrifuged for 45 min at 500 	 g. Later infections were performed by
co-culturing fetal liver cells with Phoenix cells for 2 days in the presence of Taqman Assay Reagents (PE Biosystems, Foster City, California) according
to the manufacturer’s instructions. GM-CSF mRNA expression was normal-100 ng/ml of stem cell factor, 20 ng/ml of IL-6, and 5 g/ml polybrene. The
cells were removed and placed in fresh media containing 1–5 ng/ml GM- ized to GAPDH. A cell line that expresses constitutively high levels of murine
GM-CSF was used as a positive control. We used a rat anti-mouse GM-CSFCSF (Peprotech) for 2 days, then analyzed by flow cytometry for EGFP
expression to determine the percent of cells infected. Infected pools were antibody from abcam (Catalog #ab7377-50; Cambridge, United Kingdom),
which was added at a final concentration of 4 g/ml to Myb cultures asexamined daily for the first 2–4 weeks in culture and the medium was
changed every 1–3 days depending on the rate of growth. Typically, cultures described in the text. We based the dose of antibody on published data
(O’Garra et al., 1989).expanded for the first 2 weeks. This was either followed by a decline in
cell numbers with death of the culture or by a plateau phase followed by
resumption in growth by 2 months. At this time, the cells were used for Acknowledgments
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